Last reviewed · How we verify
Anti-VEGF injections
Anti-VEGF injections work by binding to and inhibiting vascular endothelial growth factor (VEGF), a protein that promotes angiogenesis.
Anti-VEGF injections work by binding to and inhibiting vascular endothelial growth factor (VEGF), a protein that promotes angiogenesis. Used for Wet age-related macular degeneration, Macular edema following retinal vein occlusion, Diabetic macular edema.
At a glance
| Generic name | Anti-VEGF injections |
|---|---|
| Sponsor | Bayer |
| Drug class | Anti-angiogenic agent |
| Target | VEGF |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
This action helps to reduce the formation of new blood vessels that tumors need to grow and spread. By inhibiting VEGF, anti-VEGF injections can slow or stop the growth of certain cancers.
Approved indications
- Wet age-related macular degeneration
- Macular edema following retinal vein occlusion
- Diabetic macular edema
Common side effects
- Increased intraocular pressure
- Endophthalmitis
- Retinal detachment
Key clinical trials
- Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
- Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers (PHASE2, PHASE3)
- Acute Intra Ocular Pressure Monitoring After Aflibercept 8mg/0.07mL (NA)
- Speculum-Free Intravitreal Injection Using Cotton-Tipped Applicator Retraction: A Randomized Trial of Pain, Procedure Time, Patient Satisfaction, and Safety (NA)
- Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (PHASE3)
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis (PHASE1, PHASE2)
- RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) (PHASE2)
- Efficacy Comparison of DExamethasone Intravitreal Implant Combined With Aflibercept Versus Aflibercept Monotherapy in Treatment-naïve Inflammatory Diabetic Macular Edema Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti-VEGF injections CI brief — competitive landscape report
- Anti-VEGF injections updates RSS · CI watch RSS
- Bayer portfolio CI